Navigation Links
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Date:9/24/2009

may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

    CONTACT: Amgen, Thousand Oaks
    Christine Regan: 805-447-5476 (media U.S.)
    Wendy Woods: +41 (0) 41 3692 542 (media Europe)
    Arvind Sood: 805-447-1060 (investors)

'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
2. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
3. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
4. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
5. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
6. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
7. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
8. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
9. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... AMGN ) today announced that it will report its ... 27, 2015, after the close of the U.S. financial markets. The ... community at 2 p.m. PT. Participating in the call from Amgen ... officer, and other members of Amgen,s senior management team. ...
(Date:1/22/2015)... Institute for Clinical Research, Inc., a clinical research organization ... new textbook,  Translational Research Methods for Diabetes, Obesity and ... scientific publisher. The textbook is the first ... early phase clinical studies of new drugs for diabetes, ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has announced ... by Product, Application, Technology, End User - Global Forecast ... The infectious disease diagnostics market is expected to ... by 2019 from $12,422.8 million in 2014. Increase in ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... 6 Accumetrics, Inc., developer and marketer of the ... for measuring an individual,s response to multiple antiplatelet agents, ... financing that will raise $16.5 million in new capital. ... company into 2011, came from the company,s existing investors, ...
... Ltd. has started early Phase II clinical trial for RK-023, ... -- a new compound targeted as a treatment for androgenetic ... clinical trial in healthy male volunteers that began in 2008 ... clinical trial has been started for two purposes. One is ...
Cached Medicine Technology:Accumetrics Announces $16.5M in New Capital Financing 2Accumetrics Announces $16.5M in New Capital Financing 3R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023 2R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023 3
(Date:1/22/2015)... PA (PRWEB) January 22, 2015 Woodloch Pines, ... Mountains, has been selected by TripAdvisor as the number one ... the 6th best in the world for their annual Travelers’ ... online travel community . The website is home to millions ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... Honor of Huggies, 30th Anniversary, 30 Real Moms to be Featured ... ... of moms is,different from generations of the past. Strict definitions of ... their,roles on their terms. To celebrate its 30th anniversary, the Huggies ...
... today announced the launch of its superfast, low memory usage secure ... the PDF specs and is believed to be the smallest and ... ... 3, 2008 -- Drumlin Security (http://www.drumlinsecurity.co.uk) today announced the launch of ...
... Security as a,Service Provider (SaaS), announced today that ... Security Standard (DSS) version 1.2,released Oct. 1st by ... revised standard provides clarification and changes intended,to help ... is a Qualified Security Assessor Company (QSAC) and ...
... lives with at least one disability, CDC says , , THURSDAY, ... -- one in five people -- have some type of ... Prevention. , And a new CDC study finds that black, ... poor health at disproportionately higher rates than white or Asian ...
... The Association of,Clinical Research Organizations (ACRO) ... inaugural Clinical Outsourcing Leaders Summit with a ... research executives,November 13, 2008 in Washington, DC., ... interactive discussions,surrounding the impact of the presidential ...
... Weston Medical Publishing today,announced publication ... of Neurodegeneration,and Regeneration. (ISSN 1932-1481) This ... all aspects of neurodegeneration, neuroprotection and,neuroregeneration ... their relevance in treating neurodegenerative disorders ...
Cached Medicine News:Health News:Generation Huggies Celebrates 30 Years With 30 Moms 2Health News:Generation Huggies Celebrates 30 Years With 30 Moms 3Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 2Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 3Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 4Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 5Health News:SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2 6Health News:Minorities With Disabilities Report Poorer Health 2Health News:Clinical Outsourcing Leaders Summit Set to Convene November 13 2Health News:New Journal to Explore Neurodegenerative, Neuroprotective and Euroregenerative Therapies! 2
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is ... a method for safe, simple catheterization ... urinary tract infections. It includes ... The new EasyOff tear tab ...
... System is a latex-free unisex system ... simple catheterization designed to reduce the ... It includes a 100% latex-free Mentor ... tear tab makes it easy to ...
... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
Medicine Products: